Aortic & peripheral vascular disease
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial
Authors' conclusion
Rivaroxaban 2.5 mg twice daily plus aspirin compared with aspirin alone reduces direct healthcare costs. After acquisition costs of rivaroxaban, the lifetime cost-effectiveness of 2.5 mg twice daily plus aspirin is highly cost-effective in Canada, France, and Germany.
Study context
- Population
- Patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD) (COMPASS trial); costs in Canada, France and Germany
- Comparison
- Rivaroxaban 2.5 mg BID plus aspirin vs aspirin alone
- Primary endpoint
- Lifetime cost-effectiveness (ICER per QALY), direct healthcare system costs in USD
- Follow-up
- Lifetime horizon (in trial +33 years)
Methodological detailspatient-level data, two-state Markov model, 1-year cycle, extrapolated 33 years
- Patient-level data
- Two-state Markov model, 1-year cycle, extrapolated 33 years
Primary result
As reported in the abstract
Lifetime cost-effectiveness · in trial +33 years
Quality-adjusted life years (QALYs) gained with rivaroxaban plus aspirin
1.17
Incremental cost-effectiveness ratio (ICER), Canada
$3946/QALY
ICER, France
$9962/QALY
ICER, Germany
$10 264/QALY
Further findings
In-trial costs (mean follow-up 23 months)
- Costs of events and procedures reduced with rivaroxaban plus aspirin
- Adding rivaroxaban increased total costs for the combination
ICER, PAD and polyvascular disease subgroups
- Lower ICERs in PAD and polyvascular disease subgroups
Original publication
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. Eur Heart J Qual Care Clin Outcomes. Published 24 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →